



Sales

- Q1FY15 at Rs. 991 crore, decline of 27.0% over Q1FY14.


EBITDA

- Q1FY15 at Rs. 61 crore, decline of 85.5% over Q1FY14.
- Margins at 6.2% for Q1FY15 compared to 31.0% in Q1FY14.

PAT

- Q1FY15 at Rs. 20 crore, decline of 93.8% over Q1FY14.
- Margins at 2.0% for Q1FY15 compared to 23.9% in Q1FY14.

PERFORMANCE HIGHLIGHTS Q1FY15 vs. Q1FY14



- Consolidated revenues at Rs. **991** crore in **Q1FY15** versus Rs. **1358** cores in **Q1FY14**, year-on-year decline of **27.0%**.
 - USA Business declines by **60.3%** (**62.4%** in \$ terms)
 - Europe Business (excluding France) declines by **0.6%** (France grows by **68.9%**)
 - India & Emerging Markets Business grows by **16.5%**, India Business grows by **17.9%** during **Q1FY15**.
- Gross Margins at **60.9%** in **Q1FY15** versus **66.1%** in **Q1FY14**
- EBITDA at Rs. **61** crore in **Q1FY15** versus Rs. **421** crore in **Q1FY14** declines **85.5%**.
- EBITDA margins at **6.2%** in **Q1FY15** versus **31.0%** in **Q1FY14**.
- R&D Expenses at Rs. **116** crore represents **11.7%** of Sales in **Q1FY15**.
- Profit After Tax at Rs. **20** crore in **Q1FY15**.

Business Highlights

- **International operations**

- at Rs.696 crore, contributes **70.3%** of global revenues for **Q1FY15**, declines by **37.2%**

- **US Business**

- At Rs. **287** crore for the quarter.
- Contributes **29.0%** of global revenues for **Q1FY15** with decline of **60.3%** (**62.4%** on \$ basis).

- **Europe Business**

- At Rs. **297** crore (excluding France) for **Q1FY15**.
- Declines by **0.6%** (excluding France) for **Q1FY15**. France grows by **68.9%**.
- **UK markets Flat in INR terms** (decline by **14.3%** £ basis) for **Q1FY15**.
- **5th** largest generic company & **1st** largest in the hospital segment in UK.
- Irish market grows by **13.1%** (**1.8%** on € basis) for **Q1FY15**.
- largest Generic Pharma Company in Ireland.

- **India & Emerging Markets Business**

- **India Business** grows by **17.9%** in **Q1FY15**.
- **Emerging Markets (Including India)** Business grows by **16.5%** for **Q1FY15**.

Financials

Consolidated P&L

Rs. Crore

Particulars	Q1-FY15	Q1-FY14	Growth %	FY14
Revenues from Operations	991	1,358	-27.0%	4,830
Material Consumption	387	460	-15.9%	1,796
Gross Margins	604	898	-32.7%	3,034
Gross Margin %	60.9%	66.1%		62.8%
Staff Cost	177	155	14.2%	664
R&D Expenses	111	98	13.3%	403
Other Expenditure	255	224	13.8%	987
Total Expenditure	930	937	-0.7%	3,850
EBITDA	61	421	-85.5%	980
EBITDA Margin	6.2%	31.0%		20.3%
Interest & Financing Cost				
a. Interest	15	17	-11.8%	83
b. (Income)/Expense due to Exchange Rate Fluctuation	-5	21		-46
Depreciation	36	32	12.5%	140
Other Income	8	6		38
Profit/(Loss) Before Tax before exceptional items	23	357	-93.3%	841
Exceptional Item Profit/(Loss)	2	5		50
Profit/(Loss) before Tax	25	362	-92.8%	891
Provision for Taxation	1	37		2
Deferred Taxation	2	1		46
Profit/(Loss) After Tax	22	324	-92.9%	843
Add: Share of Profit/(Loss) from Associates	0	0		0
Less: Minority Interest	2	0		2
Net Profit/(Loss)	20	324	-93.5%	841
Net Profit Margin %	2.0%	23.9%		17.4%

Business Review

US Operations

USA business for Wockhardt contributed 29.0% of the Global Revenues in Q1FY15 compared to 53.2% in the Q1FY14. Revenues from the US Business were at Rs.287 crore in Q1FY15 versus Rs.722 crore in Q1FY14, representing a decline of 60.3% in INR terms and 62.4% in USD terms.

During the Quarter 13 ANDA's were filed, a total of 75 ANDA's pending for approval.

Europe Operations

Europe Operation (including France) contributed 34.6% of the Global Revenues in Q1FY15. Revenues from EU Operations (excluding France) were at Rs.297 crore in Q1FY15, representing a decline of 0.6% in INR terms in Q1FY15. Revenues from French Operations were at Rs.47 crore in Q1FY15 versus Rs.28 crore in Q1FY14, representing a growth of 68.9% in INR terms in Q1FY15.

UK Operations (including Pinewood's UK business) revenues were at Rs.237 crore in Q1FY15, versus Rs.238 crore in Q1FY14, remains Flat in Q1FY14.

Irish Business revenues were at Rs.44 crore in Q1FY15, versus Rs.39 crore in Q1FY14, representing a growth of 13.1% in INR terms in Q1FY15.

India & Emerging Markets

India and Emerging Markets contributed 36.4% of the global revenues in Q1FY15. Revenues from India and Emerging Markets were at Rs.361 crore in Q1FY15, versus Rs.310 crore in Q1FY14, representing a growth of 16.5% in Q1FY15.

- India Business grows by 17.9% during Q1FY15.
- Emerging Markets business grows by 10.3% during the quarter.
- 16 New products launched in Domestic Market during Q1FY15.

Status Update on Recent Events

The status on the Import alerts on the Chikalthana and Waluj facility remains unchanged. The Companies effort to put the remediation measures in place continues.

About Wockhardt

Wockhardt is a highly technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 850 scientists, of whom 80 are doctorates. In all, Wockhardt has 284 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8600 people from 21 different nationalities.

Disclaimer

Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof.

Contact Information

Tushar Mistry at tmistry@wockhardt.com